US pharmaceutical and medical device company Johnson and Johnson is reported to have developed a vaccine that, in early trials, shows a strong immune response to the novel coronavirus in a single dose, an interim report published on the medical website medRxiv has revealed.
“The safety profile and immunogenicity after only a single dose are supportive for further clinical development of [vaccine] Ad26.COV2.S at a dose level of 5×1010 vp, as a potentially protective vaccine against COVID-19,” the report said on Friday. “A single dose of Ad26.COV2.S elicited strong humoral responses in the vast majority of vaccine recipients.”
Continue reading https://sptnkne.ws/DMb3